(BDX) Becton Dickinson - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 39.223m USD | Total Return: 8.1% in 12m

Medical Devices, Diagnostic Equipment, Laboratory Supplies, Drug Delivery
Total Rating 42
Safety 77
Buy Signal 0.09
Medical Instruments & Supplies
Industry Rotation: +4.1
Market Cap: 39.2B
Avg Turnover: 480M
Risk 3d forecast
Volatility28.2%
VaR 5th Pctl4.50%
VaR vs Median-3.21%
Reward TTM
Sharpe Ratio0.26
Rel. Str. IBD23
Rel. Str. Peer Group50
Character TTM
Beta0.444
Beta Downside0.532
Hurst Exponent0.567
Drawdowns 3y
Max DD40.06%
CAGR/Max DD-0.18
CAGR/Mean DD-0.37
EPS (Earnings per Share) EPS (Earnings per Share) of BDX over the last years for every Quarter: "2021-03": 3.19, "2021-06": 2.74, "2021-09": 2.59, "2021-12": 3.64, "2022-03": 3.18, "2022-06": 2.66, "2022-09": 2.75, "2022-12": 2.98, "2023-03": 2.86, "2023-06": 2.96, "2023-09": 3.42, "2023-12": 2.68, "2024-03": 3.17, "2024-06": 3.5, "2024-09": 3.81, "2024-12": 3.43, "2025-03": 3.35, "2025-06": 3.68, "2025-09": 3.96, "2025-12": 2.91, "2026-03": 2.9,
EPS CAGR: 2.33%
EPS Trend: 52.3%
Last SUE: -1.90
Qual. Beats: -2
Revenue Revenue of BDX over the last years for every Quarter: 2021-03: 4907, 2021-06: 4607, 2021-09: 5135, 2021-12: 4718, 2022-03: 4750, 2022-06: 4641, 2022-09: 4761, 2022-12: 4586, 2023-03: 4821, 2023-06: 4878, 2023-09: 5087, 2023-12: 4706, 2024-03: 5045, 2024-06: 4990, 2024-09: 5437, 2024-12: 5168, 2025-03: 5272, 2025-06: 5509, 2025-09: 5890, 2025-12: 5252, 2026-03: 4714,
Rev. CAGR: 0.42%
Rev. Trend: 65.1%
Last SUE: 0.65
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Confidence

Description: BDX Becton Dickinson

Becton, Dickinson and Company (BDX) is a global medical technology company that develops and manufactures a broad range of medical supplies, laboratory equipment, and diagnostic products. The company operates through specialized segments including Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. Its portfolio spans from high-volume consumables like syringes and catheters to complex systems for medication management, genomics, and surgical intervention.

The company operates within the Health Care Equipment sub-industry, a sector characterized by high research and development costs and rigorous regulatory oversight. BDX utilizes a diversified business model that balances recurring revenue from disposable medical supplies with long-term capital placements in pharmacy automation and diagnostic laboratory systems. This integration into hospital workflows often creates high switching costs for healthcare providers.

Investors can further evaluate these operational segments and historical performance trends by reviewing the detailed analytics on ValueRay.

Headlines to Watch Out For
  • Alaris infusion pump remediation and regulatory clearance drive core medical segment recovery
  • Expansion of high-margin prefillable syringe capacity supports long-term biopharma systems growth
  • Hospital capital expenditure cycles influence demand for automated medication dispensing systems
  • Strategic acquisitions in the interventional segment diversify revenue beyond traditional medical supplies
Piotroski VR‑10 (Strict) 6.0
Net Income: 1.14b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.43 > 1.0
NWC/Revenue: -2.32% < 20% (prev 4.67%; Δ -6.99% < -1%)
CFO/TA 0.08 > 3% & CFO 3.90b > Net Income 1.14b
Net Debt (16.47b) to EBITDA (4.16b): 3.95 < 3
Current Ratio: 0.94 > 1.5 & < 3
Outstanding Shares: last quarter (280.6m) vs 12m ago -2.96% < -2%
Gross Margin: 46.48% > 18% (prev 0.45%; Δ 4.60k% > 0.5%)
Asset Turnover: 40.58% > 50% (prev 38.31%; Δ 2.27% > 0%)
Interest Coverage Ratio: 3.75 > 6 (EBITDA TTM 4.16b / Interest Expense TTM 563.0m)
Altman Z'' 1.95
A: -0.01 (Total Current Assets 8.01b - Total Current Liabilities 8.51b) / Total Assets 50.83b
B: 0.34 (Retained Earnings 17.39b / Total Assets 50.83b)
C: 0.04 (EBIT TTM 2.11b / Avg Total Assets 52.65b)
D: 0.60 (Book Value of Equity 16.00b / Total Liabilities 26.70b)
Altman-Z'' Score: 1.95 = BBB
Beneish M -3.34
DSRI: 0.71 (Receivables 2.21b/3.03b, Revenue 21.36b/20.87b)
GMI: 0.96 (GM 46.48% / 44.50%)
AQI: 1.01 (AQ_t 0.72 / AQ_t-1 0.72)
SGI: 1.02 (Revenue 21.36b / 20.87b)
TATA: -0.05 (NI 1.14b - CFO 3.90b) / TA 50.83b)
Beneish M-Score: -3.34 (Cap -4..+1) = AA
What is the price of BDX shares? As of May 20, 2026, the stock is trading at USD 146.95 with a total of 3,053,565 shares traded.
Over the past week, the price has changed by -0.38%, over one month by -7.37%, over three months by -18.95% and over the past year by +8.06%.
Is BDX a buy, sell or hold? Becton Dickinson has received a consensus analysts rating of 3.59. Therefor, it is recommend to hold BDX.
  • StrongBuy: 4
  • Buy: 2
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BDX price?
Analysts Target Price 183.3 24.7%
Becton Dickinson (BDX) - Fundamental Data Overview as of 20 May 2026
P/E Trailing = 24.7997
P/E Forward = 11.9048
P/S = 1.7647
P/B = 1.7062
P/EG = 1.156
Revenue TTM = 21.36b USD
EBIT TTM = 2.11b USD
EBITDA TTM = 4.16b USD
Long Term Debt = 17.62b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.57b USD (from shortTermDebt, last quarter)
Debt = 20.19b USD (corrected: LT Debt 17.62b + ST Debt 2.57b)
Net Debt = 16.47b USD (from netDebt column, last quarter)
Enterprise Value = 58.60b USD (39.22b + Debt 20.19b - CCE 816.0m)
Interest Coverage Ratio = 3.75 (Ebit TTM 2.11b / Interest Expense TTM 563.0m)
EV/FCF = 18.65x (Enterprise Value 58.60b / FCF TTM 3.14b)
FCF Yield = 5.36% (FCF TTM 3.14b / Enterprise Value 58.60b)
FCF Margin = 14.71% (FCF TTM 3.14b / Revenue TTM 21.36b)
Net Margin = 5.33% (Net Income TTM 1.14b / Revenue TTM 21.36b)
Gross Margin = 46.48% ((Revenue TTM 21.36b - Cost of Revenue TTM 11.44b) / Revenue TTM)
Gross Margin QoQ = 45.69% (prev 44.63%)
Tobins Q-Ratio = 1.15 (Enterprise Value 58.60b / Total Assets 50.83b)
Interest Expense / Debt = 0.74% (Interest Expense 149.0m / Debt 20.19b)
Taxrate = 10.84% (204.0m / 1.88b)
NOPAT = 1.88b (EBIT 2.11b * (1 - 10.84%))
Current Ratio = 0.94 (Total Current Assets 8.01b / Total Current Liabilities 8.51b)
Debt / Equity = 0.84 (Debt 20.19b / totalStockholderEquity, last quarter 24.13b)
Debt / EBITDA = 3.95 (Net Debt 16.47b / EBITDA 4.16b)
Debt / FCF = 5.24 (Net Debt 16.47b / FCF TTM 3.14b)
Total Stockholder Equity = 25.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.16% (Net Income 1.14b / Total Assets 50.83b)
RoE = 4.54% (Net Income TTM 1.14b / Total Stockholder Equity 25.07b)
RoCE = 4.95% (EBIT 2.11b / Capital Employed (Equity 25.07b + L.T.Debt 17.62b))
RoIC = 4.21% (NOPAT 1.88b / Invested Capital 44.74b)
WACC = 5.20% (E(39.22b)/V(59.42b) * Re(7.54%) + D(20.19b)/V(59.42b) * Rd(0.74%) * (1-Tc(0.11)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -82.22 | Cagr: -1.66%
[DCF] Terminal Value 88.02% ; FCFF base≈2.92b ; Y1≈3.44b ; Y5≈5.29b
[DCF] Fair Price = 499.8 (EV 154.19b - Net Debt 16.47b = Equity 137.72b / Shares 275.5m; r=6.0% [WACC]; 5y FCF grow 19.05% → 3.0% )
EPS Correlation: 52.35 | EPS CAGR: 2.33% | SUE: -1.90 | # QB: -2
Revenue Correlation: 65.07 | Revenue CAGR: 0.42% | SUE: 0.65 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.13 | Chg30d=+1.39% | Revisions=+60% | Analysts=12
EPS current Year (2026-09-30): EPS=12.55 | Chg30d=+0.66% | Revisions=+69% | GrowthEPS=-12.8% | GrowthRev=-12.1%
EPS next Year (2027-09-30): EPS=13.45 | Chg30d=-0.44% | Revisions=+33% | GrowthEPS=+7.1% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: +69%